Janux Therapeutics, Inc.

NasdaqGM:JANX Stock Report

Market Cap: US$2.9b

Janux Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:JANX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
01 Nov 24SellUS$24,385,695Avalon Ventures, LLCCompany456,267US$55.26
01 Nov 24SellUS$391,382Sanford MadiganIndividual7,371US$53.12
01 Nov 24SellUS$243,671Jay LichterIndividual4,558US$53.51
01 Nov 24SellUS$1,730,817Tighe ReardonIndividual32,384US$53.82
01 Nov 24SellUS$334,250Sergio DuronIndividual6,306US$53.02
01 Nov 24SellUS$2,337,413Avalon Bio VenturesCompany43,734US$55.26
24 Oct 24SellUS$262,634Jay LichterIndividual4,921US$53.37
24 Oct 24SellUS$1,802,808Tighe ReardonIndividual34,799US$52.77
23 Oct 24SellUS$25,244,312Avalon Ventures, LLCCompany492,469US$53.36
23 Oct 24SellUS$408,358Sanford MadiganIndividual7,954US$51.34
23 Oct 24SellUS$350,101Sergio DuronIndividual6,806US$51.44
23 Oct 24SellUS$2,419,661Avalon Bio VenturesCompany47,203US$53.36
18 Oct 24SellUS$21,101,095Avalon Ventures, LLCCompany420,066US$51.18
18 Oct 24SellUS$2,022,474Avalon Bio VenturesCompany40,262US$51.18
18 Oct 24BuyUS$53,700,000RA Capital Management, L.P.Company1,200,000US$44.75
18 Oct 24SellUS$49,003,174Avalon Ventures, LLCCompany1,095,043US$44.75
18 Oct 24SellUS$4,696,826Avalon Bio VenturesCompany104,957US$44.75
17 Oct 24SellUS$26,155Jay LichterIndividual516US$50.80
30 Sep 24SellUS$5,221Jay LichterIndividual113US$46.24
27 Sep 24SellUS$12,924,676Avalon Ventures, LLCCompany275,255US$47.77
27 Sep 24SellUS$1,239,338Avalon Bio VenturesCompany26,394US$47.77
27 Sep 24SellUS$145,750Avalon Ventures, LLCCompany3,053US$47.74
27 Sep 24SellUS$13,988Avalon Bio VenturesCompany293US$47.74
12 Sep 24SellUS$1,850,216Avalon Bio VenturesCompany39,455US$47.00
12 Sep 24SellUS$19,303,403Avalon Ventures, LLCCompany411,636US$47.00
09 Sep 24SellUS$9,198,378Avalon Ventures, LLCCompany219,009US$42.00
09 Sep 24SellUS$3,513Jay LichterIndividual83US$42.33
09 Sep 24SellUS$881,622Avalon Bio VenturesCompany20,991US$42.00
31 Jul 24SellUS$61,511,990OrbiMed Advisors LLCCompany1,312,787US$55.01
03 Jun 24SellUS$74,942,019Avalon Ventures, LLCCompany1,368,804US$54.75
03 Jun 24SellUS$7,182,981Avalon Bio VenturesCompany131,196US$54.75
02 Mar 24SellUS$757,732Sanford MadiganIndividual16,341US$46.37
02 Mar 24SellUS$560,125Sergio DuronIndividual12,343US$45.38

Insider Trading Volume

Insider Buying: JANX insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of JANX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders4,069,8487.6%
VC/PE Firms10,365,65219.4%
Institutions39,123,21173%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.7%.

Top Shareholders

Top 25 shareholders own 90.17% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
19.8%
RA Capital Management, L.P.
10,365,652US$581.9m13.1%7.34%
14.9%
FMR LLC
7,824,671US$439.3m0.61%0.03%
5.72%
Klaus Dorner
2,999,990US$168.4m-21.7%no data
4.97%
Paradigm Biocapital Advisors LP
2,608,574US$146.4m8.66%5.52%
4.81%
Janus Henderson Group plc
2,523,406US$141.7m40%0.06%
4.62%
BlackRock, Inc.
2,422,636US$136.0m3.35%no data
3.95%
Adage Capital Management, L.P.
2,075,000US$116.5m-10.9%0.21%
3.56%
Avalon Ventures, LLC
1,869,633US$105.0m-67.2%84.87%
3.52%
The Vanguard Group, Inc.
1,847,930US$103.7m18.3%no data
3.05%
Woodline Partners LP
1,600,263US$89.8m432%0.8%
2.8%
EcoR1 Capital, LLC
1,469,818US$82.5m0%2.91%
2.59%
State Street Global Advisors, Inc.
1,361,178US$76.4m-2.86%no data
2.4%
OrbiMed Advisors LLC
1,258,566US$70.7m-57.8%1.03%
2%
Cormorant Asset Management, LP
1,050,000US$58.9m0%3.29%
1.91%
Logos Global Management, L.P.
1,000,000US$56.1m33.3%7.09%
1.9%
Citadel Advisors LLC
999,606US$56.1m-35.8%0.06%
1.34%
Lord, Abbett & Co. LLC
703,481US$39.5m0.12%0.12%
1.26%
Geode Capital Management, LLC
662,594US$37.2m6.17%no data
1.07%
Avidity Partners Management, L.P.
562,000US$31.6m-33.1%1.86%
0.92%
Vestal Point Capital, LP
485,000US$27.2m-33.1%2.26%
0.9%
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.
471,736US$26.5m0%0.24%
0.75%
Point72 Asset Management, L.P.
395,875US$22.2m190%0.06%
0.51%
Northern Trust Global Investments
266,498US$15.0m37.1%no data
0.49%
Goldman Sachs Group, Investment Banking and Securities Investments
257,400US$14.5m-14.2%0.01%
0.46%
David Campbell
242,054US$13.6m-90.9%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 16:15
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Janux Therapeutics, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Kaveri PohlmanBTIG
Justin ZelinBTIG